References
- Medawar PB. The behaviour and fate of skin autografts and skin homografts in rabbits: A report to the War Wounds Committee of the Medical Research Council. J Anat. 1944;78(Pt 5:176-99. PMID: 17104960
- Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953 Oct 3;172(4379):603-606. doi: 10.1038/172603a0
- Starzl TE. History of clinical transplantation. World J Surg. 2000 Jul;24(7):759-82. doi: 10.1007/s002680010124
- Murray JE, Merrill JP, Dammin GJ, Dealy, JB
Jr , Alexandre GW, Harrison JH. Kidney transplantation in modified recipients. Ann Surg. 1962 Sep;156(3):337-55. doi: 10.1097/00000658-196209000-00002 - Starzl TE, Marchioro TL, Waddell WR. The Reversal of Rejection in Human Renal Homografts with Subsequent Development of Homograft Tolerance. Surg Gynecol Obstet. 1963 Oct;117: 385-95. PMID:14065716
- Kuss R, Legrain M, Mathe G, Nedey R, Camey M. Homologous human kidney transplantation. Experience with six patients. Postgrad Med J. 1962 Sep;38(443):528-31. doi: 10.1136/pgmj.38.443.528
- Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet. 1967 Feb;124(2):301-308. PMID: 4163340
- Levey RH, Medawar PB. Nature and mode of action of antilymphocytic antiserum. Proc Natl Acad Sci USA. 1966 Oct;56(4):1130-1137. doi: 10.1073/pnas.56.4.1130
- Barnard CN. What we have learned about heart transplants. J Thorac Cardiovasc Surg. 1968 Oct;56(4):457-68. PMID: 4879092
- Stehlik J, Kobashigawa J, Hunt SA, Reichenspurner H, Kirklin JK. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. Circulation. 2018 Jan 2;137(1):71-87. doi: 10.1161/CIRCULATIONAHA.117.029753
- Robbins RC, Barlow CW, Oyer PE, Hunt SA, Miller JL, Reitz BA, Stinson EB, Shumway NE. Thirty years of cardiac transplantation at Stanford University. J Thorac Cardiovasc Surg 1999 117, 939-951. doi: 10.1016/S0022-5223(99)70375-2
- Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979 Nov 17;2(8151):1033-36. doi: 10.1016/s0140-6736(79)92440-1
- Opelz G. Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study. Transplant Proc. 1997 Feb-Mar;29(1-2):617-9. doi: 10.1016/s0041-1345(96)00327-2
- Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med. 1983 Oct 6;309(14):809-15. doi: 10.1056/NEJM198310063091401
- Kolata G. Drug Transforms Transplant Medicine. Science. 1983 Jul 1;221(4605):40-42. doi: 10.1126/science.6407111
- Marino J, Paster J, Benichou G. Allorecognition by T Lymphocytes and Allograft Rejection. Front Immunol. 2016 Dec 14;7:582. doi: 10.3389/fimmu.2016.00582
- Li XC, Jevnikar AM.
Transplant Immunology , 1st edition. 2016. Hoboken, NJ: Wiley-Blackwell; 2015. 368 p. - Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol. 1993;11:385-402. doi: 10.1146/annurev.iy.11.040193.002125
- Zhanzak Z, Johnson AC, Foster P, et al. Identification of indirect CD4(+ T cell epitopes associated with transplant rejection provides a target for donor-specific tolerance induction. Immunity. 2025 Feb 11;58(2):448-464. doi: 10.1016/j.immuni.2025.01.008
- Gokmen MR, Lombardi G, Lechler RI. The importance of the indirect pathway of allorecognition in clinical transplantation. Curr Opin Immunol. 2008 Oct;20(5):568-74. doi: 10.1016/j.coi.2008.06.009
- Noorchashm H, Reed AJ, Rostami SY, et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol. 2006 Dec 1;177(11):7715-22. doi: 10.4049/jimmunol.177.11.7715
- Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: An ISHLT consensus document. J Heart Lung Transplant. 2018 May;37(5):537-547. doi: 10.1016/j.healun.2018.01.1291
- Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of belatacept. Am J Transplant. 2012 Mar;12(3):554-562. doi: 10.1111/j.1600-6143.2011.03976.x
- Krishnamoorthy V, Kannanganat S, Maienschein-Cline M, et al. The IRF4 Gene Regulatory Module Functions as a Read-Write Integrator to Dynamically Coordinate T Helper Cell Fate. Immunity. 2017 Sep 19;47(3):481-497.e7. doi: 10.1016/j.immuni.2017.09.001
- Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013 Feb 15;95(3):410-417. doi: 10.1097/TP.0b013e31827d62e3
- Clemmensen TS, Hjort Baatrup J, Bjerre KP, Lichscheidt E, Nielsen PK, Eiskjaer H. Routine screening for HLA Antibodies in Heart Transplant patients-Does it affect clinical decision making? Clin Transplant. 2024 Mar;38(3):
e15281 . doi: 10.1111/ctr.15281 - Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005 Oct 27;80(8):1019-25. doi: 10.1097/01.tp.0000180564.14050.49
- Stastny P, Lavingia B, Fixler DE, Yancy CW, Ring WS. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation. 2007 Sep 27;84(6):738-45. doi: 10.1097/01.tp.0000281918.51138.3f
- Habal MV, Miller AMI, Rao S, et al. T cell repertoire analysis suggests a prominent bystander response in human cardiac allograft vasculopathyk. Am J Transplant. 2021 Apr;21(4):1465-1476. doi: 10.1111/ajt.16333
- Akimova T, Kamath BM, Goebel JW, et al. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant. 2012 Dec;12(12):3449-61. doi: 10.1111/j.1600-6143.2012.04269.x
- Seo H, Chen J, Gonzalez-Avalos E, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+ T cell exhaustion. Proc Natl Acad Sci USA. 2019 Jun 18;116(25):12410-12415. doi: 10.1073/pnas.1905675116
- Khush KK, Hsich E, Potena L, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant. 2021 Oct;40(10):1035-1049. doi: 10.1016/j.healun.2021.07.015
- Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998 Aug 27;66(4):507-15. doi: 10.1097/00007890-199808270-00016
- Eisen HJ, Kobashigawa J, Keogh A, et al. 2005 Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005 May;24(5):517-25. doi: 10.1016/j.healun.2005.02.002
- Braithwaite HE, Darley DR, Brett J, Day RO, Carland JE. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review. Transplant Rev (Orlando). 2021 Apr;35(2):
100610 . doi: 10.1016/j.trre.2021.100610 - Kobashigawa J. Clinical trials in heart transplantation: The evolution of evidence in immunosuppression. J Heart Lung Transplant. 2017 Dec;36(12):1286-1290. doi: 10.1016/j.healun.2017.10.009
- Kobashigawa J, Dadhania DM, Farr M, et al. Consensus Conference on Heart-Kidney Transplantation. Am J Transplant. 2021 Jul;21(7):2459-2467. doi: 10.1111/ajt.16512
- Fortrie G, Constantinescu AA, van de Woestijne PC, Betjes MG. Renal function at 1 year after cardiac transplantation but not acute kidney injury is highly associated with long-term survival and loss of renal function - a retrospective cohort study. Transplant Int. 2017 Aug;30(8):788-798. doi: 10.1111/tri.12940
- Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002 Oct;2(9):807-18. doi: 10.1034/j.1600-6143.2002.20902.x
- Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019 Oct;38(10):1056-1066. doi: 10.1016/j.healun.2019.08.001
- Nikolova AP, Kobashigawa JA. Cardiac Allograft Vasculopathy: The Enduring Enemy of Cardiac Transplantation Transplantation. 2019 Jul;103(7):1338-1348. doi: 10.1097/TP.0000000000002704
- Andreassen AK, Andersson B, Gustafsson F, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug;14(8):1828-38. doi: 10.1111/ajt.12809
- Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013 May;13(5):1203-16. doi: 10.1111/ajt.12181
- Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil MMF or sirolimus vs cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006 Jun;6(6):1377-86. doi: 10.1111/j.1600-6143.2006.01290.x
- Gustafsson F, Andreassen AK, Andersson B, et al. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. Transplantation. 2020 Jan;104(1):154-164. doi: 10.1097/TP.0000000000002702
- Barten MJ, Hirt SW, Garbade J, et al. Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study. Am J Transplant. 2019 Mar 18. doi: 10.1111/ajt.15361
- Asleh R, Briasoulis A, Kremers WK, et al. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. J Am Coll Cardiol. 2018 Feb 13;71(6):636-650. doi: 10.1016/j.jacc.2017.12.005
- Asleh R, Alnsasra H, Lerman A, et al. Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients. Am J Transplant. 2021 Feb;21(2):626-635. doi: 10.1111/ajt.16155
- Inglis SS, Abbas M, Asleh R, et al. Incidence and risk factors for rejection after conversion from calcineurin inhibitor to sirolimus-based immunosuppression in orthotopic heart transplant recipients. J Heart Lung Transplant. 2024 Dec 30;S1053-2498(24)02027-8. doi: 10.1016/j.healun.2024.12.014
- Kampaktsis PN, Doulamis IP, Asleh R, et al. Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database. J Am Heart Assoc. 2022 Sep 6;11(17):
e025507 . doi: 10.1161/JAHA.122.025507 - Jennings DL, Lange N, Shullo M, et al. Outcomes associated with mammalian target of rapamycin mTOR inhibitors in heart transplant recipients: A meta-analysis. Int J Cardiol. 2018 Aug 15;265:71-76. doi: 10.1016/j.ijcard.2018.03.111
- Gonzalez-Vilchez F, Vazquez de Prada JA, Paniagua MJ, et al. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Int J Cardiol. 2014 Jan 15;171(1):15-23. doi: 10.1016/j.ijcard.2013.11.036
- Salehi S, Sosa RA, Jin YP, et al. Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection. Am J Transplant. 2018 May;18(5):1096-1109. doi: 10.1111/ajt.14544
- Jin YP, Valenzuela NM, Zhang X, Rozengurt E, Reed EF. HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection. J Immunol. 2018 Feb 23;200(7):2372-2390. doi: 10.4049/jimmunol.1701259
- Wang C, Yi T, Qin L, et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest. 2013 Mar 8;123(4):1677-1693. doi: 10.1172/JCI66204
- Diaz-Molina B, Diaz-Bulnes P, Carvajal Palao R, et al. Early Everolimus Initiation Fails to Counteract the Cytotoxic Response Mediated by CD8(+ T and NK Cells in Heart Transplant Patients. Front Immunol. 2018 Sep 26;9:
2181 . doi: 10.3389/fimmu.2018.02181 - June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol. 1987 Dec;7(12):4472-4481. doi: 10.1128/mcb.7.12.4472-4481.1987
- Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 1989 Apr 21;244(4902):339-43. doi: 10.1126/science.2540528
- Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA. 1989 Feb;86(4):1333-7. doi: 10.1073/pnas.86.4.13333
- Turka LA, Ledbetter JA, Lee K, June CH, Thompson CB. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol. 1990 Mar 1;144(5):1646-53. PMID: 2155264
- Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005 Mar;5(3):443-53. doi: 10.1111/j.1600-6143.2005.00749.x
- Ruderman EM, Pope RM. The evolving clinical profile of abatacept CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther. 2005:7 Suppl 2(Suppl 2):S21-25. doi: 10.1186/ar1688
- Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005 Aug 25;353(8):770-81. doi: 10.1056/NEJMoa050085
- Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors BENEFIT-EXT study). Am J Transplant. 2010 Mar;10(3):547-57. doi: 10.1111/j.1600-6143.2010.03016.x
- Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients BENEFIT study). Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x
- Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016 Jan 29;374(4):333-43. doi: 10.1056/NEJMoa1506027
- Bray RA, Gebel HM, Townsend R, et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant. 2018 Jul;18(7):1783-1789. doi: 10.1111/ajt.14721
- ATC [Internet]. Mount Laurel, NJ: American Transplant Congress; c2025. Everly M, Jucaud V, Roberts M, Gebel HM, Bray RA.
Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts ; 2017 suppl 3 [cited 2025 Apr 27]. Available from:https://atcmeetingabstracts.com/abstract/immunogenic-hla-mismatches-and-evidence-that-belatacept-may-be-the-first-therapy-able-to-prevent-dq-de-novo-dsa-an-analysis-of-the-benefit-and-benefit-ext-trial-cohorts/ - Bray RA, Gebel HM, Townsend R, et al. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT. Am J Transplant. 2018 Apr 17;18(7):1774-1782. doi: 10.1111/ajt.14738
- Yang J, Chen J, Young JS, et al. Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation. Transplantation, 2016 Aug;100(8):1683-91. doi: 10.1097/TP.0000000000001253
- Young JS, Chen J, Miller ML, et al. Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection. Am J Transplant. 2016 Aug;16(8):2312-23. doi: 10.1111/ajt.1376
- Cohen JB, Eddinger KC, Forde KA, Abt PL, Sawinski D. Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study. Transplantation. 2017 Oct;101(10):2582-2589. doi: 10.1097/TP.0000000000001589
- Adams AB, Goldstein J, Garrett C, et al. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. Am J Transplant. 2017 Nov;17(11):2922-2936. doi: 10.1111/ajt.14353
- de Graav GN, Baan CC, Clahsen-van Groningen MC, et al. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. Transplantation. 2017 Oct;101(10):2571-2581. doi: 10.1097/TP.0000000000001755
- Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014 Aug;14(8):1817-27. doi: 10.1111/ajt.12810
- Bertrand D, Chavarot N, Olagne J, et al. Biopsy-Proven T-Cell Mediated Rejection After Belatacept Rescue Conversion: A Multicenter Retrospective Study. Transpl Int. 2024 Dec 6;37:
13544 . doi: 10.3389/ti.2024.13544 - Divard G, Aubert O, Debiais-Deschamp C, et al. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2024 May 1;19(5):628-637. doi: 10.2215/CJN.0000000000000411
- Launay M, Guitard J, Dorent R, et al. Belatacept-based immunosuppression: A calcineurin inhibitor-sparing regimen in heart transplant recipients. Am J Transplant. 2020 Feb;20(2):553-563. doi: 10.1111/ajt.15584
- Schenk AD, Anderson DJ, Cole RT, Badell IR, Larsen CP. De Novo Belatacept in a Kidney-After-Heart Transplant Recipient. Transplant Direct. 2019 Dec 24;6(1):
e515 . doi: 10.1097/TXD.0000000000000967 - Ford ML. T Cell Cosignaling Molecules in Transplantation. Immunity. 2016 May 17;44(5):1020-1033. doi: 10.1016/j.immuni.2016.04.012
- Budde K, Prashar R, Haller H, et al. Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial. J Am Soc Nephrol. 2021 Dec 1;32(12):3252-3264. doi: 10.1681/ASN.2021050628
- Karadkhele G, Hogan J, Magua W, et al. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. Am J Transplant. 2021 Jan;21(1):208-221. doi: 10.1111/ajt.16132
- Kirk AD, Adams AB, Durrbach A, et al. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. Am J Transplant. 2021 May;21(5):1691-1698. doi: 10.1111/ajt.16386
- Johnson AC, Zhang J, Karadkhele G, Gragert L, Hertzberg V, Larsen CP. Belatacept with time-limited tacrolimus coimmunosuppression modifies the 3-year risk of eplet mismatch in kidney transplantation. Am J Transplant. 2024 Feb;24(2):260-270. doi: 10.1016/j.ajt.2023.09.011
- Wojciechowski D, Chandran S, Yang JYC, Sarwal MM, Vincenti F. Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience. Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13042
- Li S, Gao Q, Xu H, Kirk AD. Rapamycin Prevents Expansion of Costimulation Blockade-resistant CD8+ Alloreactive Memory Cells following Depletional Induction in Renal Transplant Recipients. J Immunol. 2024 Nov 1;213(9):1305-1317. doi: 10.4049/jimmunol.2400146
- Heeger PS, Haro MC, Jordan S. Translating B cell immunology to the treatment of antibody-mediated allograft rejection. Nat Rev Nephrol. 2024 Apr;20(4):218-232. doi: 10.1038/s41581-023-00791-0
- Franco-Acevedo A, Pathoulas CL, Murphy PA, Valenzuela NM. The Transplant Bellwether: Endothelial Cells in Antibody-Mediated Rejection. J Immunol. 2023 Nov 1;211(9):1276-1285. doi: 10.4049/jimmunol.2300363
- Halloran PF, Madill-Thomsen K, Aliabadi-Zuckermann AZ, et al. Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival. Am J Transplant. 2024 Aug;24(8):1414-1426. doi: 10.1016/j.ajt.2024.03.031
- Russum S, Sayin I, Shwetar J, et al. Donor HLA-DQ reactive B cells clonally expand under chronic immunosuppression and include atypical CD21 low CD27 - B cells with high-avidity germline B-cell receptors. bioRxiv [Preprint]. 2024 Dec 10;2024.12.06.627284. doi: 10.1101/2024.12.06.627284
- Elsner RA, Shlomchik MJ. Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity. Immunity. 2020 Dec 15;53(6):1136-1150. doi: 10.1016/j.immuni.2020.11.006
- Eskandary F, Regele H, Baumann L, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818
- Kwun J, Burghuber C, Manook M, et al. Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. J Am Soc Nephrol. 2017 Jul;28(7):1991-1996. doi: 10.1681/ASN.2016070727
- Hill JA, Kiem ES, Bhatti A, et al. Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy. Am J Transplant. 2023 Mar;23(3):416-422. doi: 10.1016/j.ajt.2022.11.001
- Jain D, Rajab A, Young JS, et al. Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant. 2020 Oct;20(10):2675-2685. doi: 10.1111/ajt.15881
- Manook M, Olaso D, Anwar IJ, et al. Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant. Sci Adv. 2023 May 19;9(20):
eadg1448 . doi: 10.1126/sciadv.adg1448 - Schroder PM, Fitch ZW, Schmitz R, Choi AY, Kwun J, Knechtle SJ. The past, present, and future of costimulation blockade in organ transplantation. Curr Opin Organ Transplant. 2019 Aug;24(4):391-401. doi: 10.1097/MOT.0000000000000656
- Goldberg JF, Tian X, Bon A, et al. Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction. Circ Heart Fail. 2024 Dec;17(12):
e011592 . doi: 10.1161/CIRCHEARTFAILURE.124.011592 - Mayer KA, Schrezenmeier E, Diebold M, et al. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. N Engl J Med. 2024 Jul 11;391(2):122-132. doi: 10.1056/NEJMoa2400763
- Muckenhuber M, Mengrelis K, Weijler AM, et al. IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice. Nat Commun. 2024 Jun 3;15(1):
4309 . doi: 10.1038/s41467-024-48574-w - Jordan SC, Ammerman N, Huang E, Vo A. Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts. Am J Transplant. 2022 Dec;22 Suppl 4:28-37. doi: 10.1111/ajt.17207
- Sawitzki B, Harden PN, Reinke P, et al. Regulatory cell therapy in kidney transplantation The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 2020 May;395(10237):1627-1639. doi: 10.1016/S0140-6736(20)30167-7
- Steiner R, Pilat N. The potential for Treg-enhancing therapies in transplantation. Clin Exp Immunol. 2023 Mar 16;211(2):122-137. doi: 10.1093/cei/uxac118
- Tang Q, Leung J, Peng Y, et al. Selective decrease of donor-reactive T(regs after liver transplantation limits T(reg therapy for promoting allograft tolerance in humans. Sci Transl Med. 2022 Nov 2;14(669):
eabo2628 . doi: 10.1126/scitranslmed.abo2628
DOI: https://doi.org/10.14797/mdcvj.1596 | Journal eISSN: 1947-6108
Language: English
Page range: 40 - 50
Submitted on: Mar 9, 2025
Accepted on: Apr 22, 2025
Published on: May 15, 2025
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2025 Marlena Habal, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.